Forbion-led syndicate supports Argos

Tuesday 24 April 2012

A syndicate led by Forbion Capital Partners of the Netherlands has secured $25 million in Series D financing for Argos Therapeutics Inc of the US to support a Phase 3 study of the company’s immunotherapy for metastatic renal cell carcinoma. The trial is being run under an SPA.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States